Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

---

Abstract Introduction: Benign Prostatic Hyperplasia is a pathologic process and main reason for lower urinary tract symptoms in old men. Its most common sign is nocturia. BPH treatment has relative response to α1-blockers and 5- α reductase Inhibitors (25-39%). Celecoxib is used as a cyclooxygenase II allocated inhibitor, low price, available drug and could be effective in decreasing the incidence of Nocturia. Objective: Survey efficacy of Celecoxib on nocturia in patients with Benign Prostatic Hyperplasia. Materials and Methods: In this clinical trial study, among patients with LUTS suggestive of BPH, 40 men those had IPSS score8 and prostate volume20cm2 were, enrolled. These patients had nocturia≥2 despite previous standard medical treatment. Patients underwent primary uroflowmetry and received 100mg celecoxib at 9pm every night along with previous treatment for 1 month. Reevaluation of disease with second uroflowmetry and determining incidence of nocturia after treatment was performed. Statistical analysis was done by chi-square test, simple t-test, and pair t-test and krusskal-wallis test. Results: Forty patients with mean age of 64.3±7.7years were studies, mean prostate size of them was 41.8±13.2cm2, initial mean IPSS score was 18.2±3.4 and initial mean Qmax was 12.5 ±2.5 ml/s. 95% of patients complained nocturia twice at night. After receiving 100mg celecoxib during 1 month, Range of received answers were appraised. The effects after treatment were assessed: excellent reaction (nocturia disappeared or decreased by 2 or more voids/night), improved reaction (nocturia decreased by 1 void/night) and unchanged reaction, obtained in 70%, 12.5% and17.5% in patients, respectively. Mean frequency of nocturia decreased from 5.17±2.1 before treatment to 2.5±1.9 after it (P<0.0001), Mean IPSS score and Mean Qmax of patients after treatment were 15.5±4.2 (P<0.0001) and 12.9±2.7 ml/s(P=0.05) respectively. Conclusions: Improved or disappeared nocturia is 82.5% in patients. The result of our study advise to use celecoxib in combination with standard medical therapy for BPH as a useful alternative treatment.

Keywords: Celecoxib, Nocturia, Prostatic Hyperplasia

Full-Text [PDF 178 kb]   (2463 Downloads)    

Add your comments about this article : Your username or Email:

---